Myristoyl pentapeptide-17:Exports & Compliance White Paper 2026

I. Executive Summary

Myristoyl Pentapeptide-17 (CAS 959610-30-1) is a synthetic N-terminally myristoylated pentapeptide amide of sequence Myr-Lys-Leu-Ala-Lys-Lys-NH2 and nominal relative molecular mass near 796 Da, carrying the INCI name Myristoyl Pentapeptide-17. It belongs to the lipopeptide class of cosmetic actives, in which a C14 acyl chain is grafted onto a short cationic sequence to yield a surface-active molecule. Traded as a lyophilised or spray-dried powder, it serves as a cosmetic raw material in eyelash, eyebrow and hair-fibre appearance products. It has no approved therapeutic indication in any major jurisdiction, is not a drug, and must never be positioned as an alternative to a medicinal product.

Because the sequence is only five residues long, manufacturing economics are driven less by the amino acids than by protecting-group strategy, lipidation selectivity, purification yield and counter-ion control. Typical campaigns assemble the chain by Fmoc/tBu solid-phase peptide synthesis on a Rink amide or Sieber amide resin, myristoylate the N-terminus on resin, then finish by reversed-phase preparative chromatography and salt exchange; kilogram programmes may migrate to solution-phase fragment condensation. What separates suppliers is rarely the advertised HPLC purity, but documented control of the des-myristoyl species, lysine side-chain over-acylation, deletion and diastereomeric sequences, residual trifluoroacetate, Class 2 residual solvents, microbial counts and heavy metals.

On the regulatory side the material is not listed in Annexes II to VI of Regulation (EC) 1223/2009, so EU market access turns on general safety, the Responsible Person's product information file and an Annex I safety assessment rather than any ingredient-specific authorisation. Gatekeepers are therefore documentation and claim discipline: CPNP notification, an Annex I-compliant CPSR, evidence accepted under Regulation (EU) 655/2013, MoCRA facility registration and product listing in the United States, REACH status with environmental endpoints, the ISO 16128 natural-index calculation, and RSPO and deforestation-due-diligence evidence for the fatty acid. Each is examined below.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

For formulators the operative point is that this molecule behaves as a cationic lipopeptide surfactant rather than as a conventional hydrophilic peptide. Its lysine side chains remain protonated across the cosmetic pH window, giving substantivity towards anionic sites on oxidised or abraded keratin, while the myristoyl chain anchors into lipid-associated regions of the hair surface. Consequently solubility, ionic compatibility with anionic rheology modifiers and preservation strategy have to be engineered rather than assumed, and commercial specifications must define the ionic form, not merely the sequence.

• Interfacial Behaviour and Aggregation: Like other single-chain cationic amphiphiles, the molecule exhibits a concentration-dependent association threshold in aqueous media, above which apparent assay, filtration behaviour and surface tension change. Buyers should therefore ask suppliers for solubility maps in water, glycols and hydroalcoholic blends rather than a single pass or fail solubility statement.
• Ionic Incompatibility Risks: Free amines form salts with carbomer and other carboxyvinyl thickeners, causing viscosity collapse and stringing, and may reduce apparent preservative availability in challenge testing. Non-ionic rheology systems and upfront ISO 11930-style compatibility screening avoid failures that are frequently misattributed to raw-material quality.

2.2 Synthesis and Manufacturing Technologies

Production routes divide into resin-based stepwise assembly, favoured for speed, reproducibility and regulatory familiarity, and solution-phase or hybrid fragment routes, favoured once annual requirements move into kilogram territory and downstream chromatography becomes the cost bottleneck. Both converge on the same critical operations: complete yet selective lipid initiation, suppression of epimerisation during activation, and isolation that fixes a defined counter-ion. Route selection should be treated as a specification decision, because impurities generated early, particularly side-chain acylated and single-residue deletion peptides, are structurally close to the target and expensive to reject later.

• Solid-Phase Assembly and On-Resin Myristoylation: Chains are built with Fmoc-protected residues activated by uronium or carbodiimide and additive systems, deprotected with piperidine, and N-acylated on resin using pre-activated myristic acid. Global cleavage with trifluoroacetic acid and scavengers liberates the peptide amide; careful scavenger and temperature control limits trifluoroacetylation of lysine side chains.
• Hybrid Routes, Chromatography and Isolation: Larger campaigns often couple a protected tripeptide to a lysine-containing fragment in solution, then perform preparative reversed-phase purification with aqueous acetonitrile gradients. Counter-ion exchange to acetate or hydrochloride, desalting by nanofiltration or size exclusion and final lyophilisation establish the delivered physical form.

2.3 Core Application Matrix

• Eyelash and Eyebrow Appearance Products: The dominant cosmetic use is in lash and brow conditioning serums and mascaras positioned as prostaglandin-analogue-free. Because such products are cosmetics, every claim must be demonstrably non-pharmacological, and any reference to growth, regrowth or a medical effect exposes both brand and supplier to regulatory action.
• Hair-Fibre and Scalp Care Compositions: Cationic substantivity supports use in leave-in conditioners, bonding-style treatments, scalp tonics and aqueous or anhydrous serums. Suppliers add value through pre-diluted solutions in pentylene glycol or glycerin-water systems that carry their own microbial control and packaging-compatibility data.
• Non-Clinical Claim-Substantiation Support: Contract houses increasingly deliver keratinocyte monolayer assays, reconstructed tissue models and hair-fibre tensile testing packages used by brands to substantiate cosmetic appearance claims. These are non-clinical laboratory studies, not clinical investigations, and must be documented and marketed as such at every point in the chain.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand has been reshaped less by consumer fashion than by reclassification risk. Lash and brow products historically associated with prostaglandin analogues attracted regulatory scrutiny and retailer de-listing pressure, prompting brands to reformulate around peptide-based actives that can be presented within a cosmetic boundary. That substitution expands volume for this sequence while raising evidential expectations, since repositioning depends on a defensible dossier rather than narrative. Buyers have shifted from spot purchasing towards framework agreements with fixed specifications, reserved volumes and technical-service clauses, interrogating documentation depth before price.

3.2 Capacity Distribution and Export Flows

Installed capability sits mainly in China's Yangtze River Delta, in Korea and Japan, and in a thinner European and North American tier of specialists and toll manufacturers. Chinese plants benefit from local access to protected amino acids, coupling reagents and resin and move quickly from quotation to kilogram campaigns; Korean and Japanese suppliers are close to brand innovation cycles and lead on dossier completeness; European and US partners command premium pricing through proximity to Responsible Person networks. Because the category is small by tonnage, few facilities dedicate capacity, so schedules depend more on queue position than on synthesis duration.

3.3 Market Bifurcation and Pricing Dynamics

The market bifurcates between cosmetic-grade material offered at high declared purity with salt, water and microbial panels attached, and cheaper laboratory-grade lots intended for formulation screening only, labelled not for incorporation into finished cosmetics until requalified. Price differentials narrow once a buyer specifies counter-ion identity, peptide content on an as-is basis, individual limits for named impurities and full batch analytics. Further drivers include protected lysine and myristic acid costs, acetonitrile availability tied to acrylonitrile economics, resin reuse policy and whether specialised low-bioburden finishing is required.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Cosmetic ingredients face a compliance architecture in which the exported molecule itself is rarely restricted; the burden falls on the finished-product Responsible Person and on the strength of the documentation offered upstream. Suppliers who internalise this reality sell more than powder: they sell a dossier capable of surviving authoritative inspection, retailer audit and competitor challenge. The following frameworks represent the minimum that any serious export programme towards the European Union, the United States or China must address when supplying this lipopeptide.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• Regulation (EC) 1223/2009, CPNP and the Annex I CPSR: Before placing on the market the Responsible Person files a Cosmetic Products Notification Portal notification and holds a product information file with Part A safety information and Part B assessment signed by a qualified safety assessor. Ingredient input typically covers identity, impurity profile, heavy metals, microbiological quality, stability and exposure conditions.
• REACH Registration, CLP Status and Environmental Endpoints: At or above one tonne per year an importer or Union-established Only Representative needs a registration covering ready biodegradability and aquatic toxicity, because cationic amphiphiles are often toxic to algae and daphnia at low concentrations. Annex XIII screening and dimethylformamide restrictions should also be anticipated.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• MoCRA facility registration, product listing and GMP: The Modernization of Cosmetics Regulation Act requires facilities to register with FDA and renew biennially, requires product listing with ingredients for each marketed cosmetic, and mandates serious adverse event reporting. Products distributed solely to licensed professionals are conditionally exempt, and the promised good manufacturing practice rule remains outstanding.
• Claim substantiation and state chemical policies: FTC substantiation and state regimes add a second layer, including California's Proposition 65 and Safe Cosmetics Programme and Washington's Toxic-Free Cosmetics Act restricting intentionally added PFAS. With no pre-market approval, evidence files held by the Responsible Person become the primary defensive asset.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Sustainability pressure on cosmetic peptides is intensifying from two directions: brand owners publishing Scope 3 reduction targets that reach into purchased goods and services, and regulators converting voluntary schemes into binding trade conditions. Suppliers unable to quantify solvent intensity, energy source and fatty-acid provenance increasingly lose tenders on sustainability scoring before technical evaluation begins. These elements are therefore not peripheral marketing material but qualification requirements.

5.1 Carbon Footprint and Circular Economy

Peptide manufacture is solvent-intensive, and process mass intensity is dominated by coupling and deprotection washes rather than by the final product mass. "Credible programmes report emissions from amino acid fermentation through final lyophilisation per kilogram of packaged active, and pursue measurable levers: replacing dimethylformamide and N-methylpyrrolidone with approved solvents, recovering acetonitrile and dichloromethane by distillation rather than incineration, reducing preparative chromatographic passes through better loading, and switching to spray drying where physical form permits. European toll manufacturers additionally face Emissions Trading System costs and carbon border adjustment exposure on upstream inputs, while Asian plants are increasingly asked for renewable-energy evidence and ISO 14064 verification.

5.2 Sustainable Sourcing and Traceability

The most consequential traceability question concerns the C14 chain. Myristic acid is frequently palm kernel or coconut derived, and where palm is involved the Roundtable on Sustainable Palm Oil chain-of-custody model must be evidenced by valid certificates rather than asserted. Because palm oleochemicals are covered goods under the EU Deforestation Regulation, operators placing them on the European market must obtain geolocation data and file due diligence statements. Vegan claims require confirmation that no tallow-derived streams enter the process, and cruelty-free positioning demands declarations covering every subcontractor, alongside awareness that China's revised regime has reduced mandatory animal testing for general cosmetics.

VI. Supply Chain Resilience and Export Logistics

Lipopeptide powders are robust relative to proteins but unforgiving of moisture, static charge and poor closure discipline, so packaging design belongs in the technical dossier: collapsed or agglomerated cakes generate complaints that resemble chemical instability. Logistics planning must also provide for retained samples, since the same lot becomes the reference if an adverse enquiry or disputed certificate arises months later.

6.1 Packaging Standards and Moisture/Contamination Control

• Moisture, Oxygen and Headspace Control: Standard packing uses a heat-sealed inner polyethylene liner with desiccant, nitrogen headspace where feasible, placed inside an aluminium or high-density polyethylene container with tamper-evident closure. Water activity below about 0.6 keeps the powder outside the microbial growth domain and supports corresponding low-risk classification arguments.
• Lot Integrity, Aliquot Format and Documentation: Multi-kilogram deliveries are often split into pre-weighed amber-glass or laminate aliquots to protect against repeated opening, each labelled with lot, peptide content on an as-is basis and counter-ion. Certificates of analysis, TSE and BSE-free statements and non-animal-origin declarations should accompany every shipment as standard.

6.2 Dangerous Goods Identification and Transit Protocols

Most dry-powder consignments move as non-regulated goods by air and sea, since peptide solids typically lack a dangerous-goods classification, but status must be confirmed per formulation: ethanolic concentrates become UN1170 Class 3 materials, and strongly acidic solutions may attract corrosive handling. Best practice is ambient shipment with temperature logging, or 2 to 8 degrees Celsius where stability data support it, avoiding extremes and prolonged customs dwell. Importers should secure binding tariff classification within Chapter 29 in advance, because authorities differ on short synthetic peptides, and should expect due-diligence scrutiny for palm-linked inputs.

VII. Enterprise Global Expansion Strategy Guide

Successful exporters in this category treat documentation as the product and the powder as evidence of it. Three actions consistently separate suppliers that win multi-year agreements from those trapped in spot transactions: assembling a dossier that anticipates regulatory questions before they are asked, pre-positioning route-to-market instruments in each destination, and removing single-source dependency through disciplined qualification and change control.

1. Assemble a product-information-file-ready dossier: Prepare identity by mass spectrometry and amino acid analysis, impurity limits for named related peptides, residual solvent and counter-ion declarations, microbial counts against ISO 17516 criteria, heavy metals referenced to ISO 17276 screening and Chinese cosmetic safety limits, plus statements covering allergens, animal testing, TSE and BSE status and industrial hygiene handling.
2. Pre-position EU, US and China route-to-market instruments: Europe requires a Responsible Person, CPNP readiness and a REACH position; the United States requires facility registration, product listing and adverse-event procedures; China requires assessment of new cosmetic ingredient status plus finished-goods registration and rigorous claim evidence. Building these instruments before tenders convert compliance from a cost into a barrier against competitors.
3. Dual-source under written change control: Qualify at least two separated sites, implement ISO 22716 cosmetic good manufacturing practice with ISO 9001 oversight, and embed a change-control clause covering resin, solvents, packing and analytical methods. Buyers should add retained-sample escrow and re-qualification triggers so that a silent process change cannot invalidate a finished-product safety assessment.

VIII. Conclusion

The commercial logic of this ingredient no longer rests on novelty: dozens of plants can nominally supply it and headline purity figures converge. Advantage has migrated to the credibility of the surrounding evidence, meaning whether des-myristoylated and side-chain-acylated impurities are named and controlled, whether counter-ion and peptide content are declared honestly, whether metals and microbial quality meet cosmetic rather than generic expectations, and whether fatty-acid provenance survives due-diligence review. Suppliers treating these as engineering parameters win framework business; those treating them as marketing lose tenders before technical evaluation.

The strategic picture points towards consolidation around suppliers able to serve three masters: cost discipline approaching commodity chemistry, documentation discipline approaching pharmaceutical standards, and traceability discipline approaching agricultural supply chains. Brands reformulating away from prostaglandin analogues will keep demand structurally supported, while MoCRA implementation, carbon border adjustment and deforestation due diligence progressively restrict the field. Organisations investing now in greener solvents, verified fatty-acid custody and dossier infrastructure will be written into supply chains that are expensive to leave.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Myristoyl Pentapeptide-17 Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Myristoyl Pentapeptide-17 supply chain:

• China - Yangtze River Delta peptide CDMO belt: Shanghai, Suzhou, Hangzhou and Nanjing host integrated operations with local protected amino acids, coupling reagents and resins, exporting through Shanghai and Ningbo. Strengths are cost, scale-up speed and flexible scheduling; diligence should focus on dimethylformamide substitution, acetonitrile recovery and documentation depth.
• Korea and Japan - application-driven peptide specialists: Korean suppliers in the Seoul and Cheongju corridor operate close to brand innovation cycles and typically lead on high-purity specifications and in-vitro claim-support packages. Japanese participants contribute premium amino acid and protected building-block quality and conservative quality-culture documentation, useful where jurisdiction-specific testing expectations are strict.
• Europe and North America - compliance-led supply networks: Italian, Spanish and Swiss toll manufacturers combine high-spec synthesis with proximity to Responsible Person networks, while US partners offer MoCRA-ready registrations and shorter import paths. Buyers pay more per gram and receive faster dossier turnaround, easier audit access and stronger recourse.